Dyslipidemia and Endocrine Disorder by Habte, Mezgebu Legesse et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Dyslipidemia and Endocrine 
Disorder
Mezgebu Legesse Habte, Etsegenet Assefa Beyene  
and Teka Obsa Feyisa
Abstract
Dyslipidemia is one of the most common risk factors for the most prevalent and 
fatal non-communicable diseases (NCDs); cardiovascular disease (CVD), cancer, 
chronic respiratory disease and diabetes and other. According to world health organi-
zation (WHO) report effective management of dyslipidemia can reduce incidence and 
mortality rate by NCDs up to 30%. Dyslipidemia negatively affects every vital organ; 
liver, kidney, heart, brain, lung and others in number of ways. In short dyslipidemia is 
defined as disorder of lipoprotein metabolism and it could be either hypolipoprotein-
emia or hyperlipoproteinemia. Endocrine disorder, poor feeding habit, physical inac-
tivity and other factors are responsible for existence of dyslipidemia. Lipocrinology 
which studies about interrelationship between lipid metabolism and endocrine 
function in normal and abnormal condition is getting essential. Currently number of 
studies explain that dyslipidemia induce endocrine dysfunction and the reverse is also 
possible. In addition, biochemical assessment of dyslipidemia is used to monitor clini-
cal course and progress of endocrinological diseases. Similarly, biochemical analysis 
of hormones helps to assess the outcome of antidyslipidemic drugs and prognoses the 
condition dyslipidemia. Most commonly dyslipidemia coexist with type 2 diabetes, 
obesity and metabolic syndrome. Abnormal distribution and accumulation fat in 
the body leads to deranged different hormones and factors secretion like adipokine, 
thereby contributing to chronic inflammation and lipotoxicity. Therefore, detailed 
and up-to-date review about lipid metabolism disorder and endocrine function are so 
essential in medicine and health science to have good service to community.
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1. Introduction
Different scientific journal define dyslipidemia in different ways but the idea 
is the same. Dyslipidemia defined as unhealthy levels of one or more kinds of the 
following lipid particles in the blood; high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), intermediate density lipoprotein (IDL), very low-density lipo-
protein (VLDL), triglycerides, cholesterol and others. In other words, dyslipidemia 
could be explained as disorder of lipoprotein metabolism and the condition could 
be either hyperlipoproteinemia or hypolipoproteinemia [1]. Higher plasma level of 
atherogenic and immunogenic lipid particles such as LDL, triacylglycerol, choles-




Lipids are water-insoluble heterogeneous organic molecules and can be 
extracted from tissues by nonpolar solvents. As a result of its nature body lipids are 
generally found compartmentalized, and could exist as membrane-associated lipids 
or droplets of triacylglycerol in adipocytes, or transported in plasma in association 
with protein. Its chemical nature makes lipids as a major source of energy for the 
body and hydrophobic barrier. In addition, lipids act as a precursor for synthesis 
important biomolecules like fat-soluble vitamins, prostaglandins and steroid 
hormones and others [3].
An endocrine gland secretes hormone into the blood and traveled to target 
cells or tissues located elsewhere in the body where they have specific receptor. 
Accordingly target cell and tissue produce unique response. Hormones are respon-
sible to regulate most biological activity in the body essential for survival and repro-
duction [4]. Every physiological activity; sleeping, drinking, feeding, growth, aging 
and others needs the involvement of hormones [5].
Hormones like leptin, insulin and adiponectin influence lipid metabolism and 
plasma lipid profile level which is associated with obesity. Leptin and adiponectin 
regulate lipid metabolism and increase fatty acid oxidation in the peripheral tissue by 
activating adenosine monophosphate (AMP) dependent kinase pathway. In addition, 
adiponectin increase insulin sensitivity to tissue thereby it decreases triacylglycerol and 
downregulate its plasma level [6]. Currently number of studies explain that dyslipid-
emia induce endocrine dysfunction and the reverse is also possible. In addition, bio-
chemical assessment of dyslipidemia is used to monitor clinical course and progress of 
endocrinological diseases. Similarly, biochemical analysis of hormones helps to assess 
the outcome of antidyslipidemic drugs and prognoses the condition dyslipidemia [7].
1.1 Dyslipidemia among non-communicable disease
Lipids are one of the most important macromolecules; used by our body as 
energy source, structural components of cell membrane, precursor for synthesis of 
steroid hormones and fat-soluble vitamins etc. There are also essential fatty acids 
like linolic and linolenic which are necessary for normal biological activity and 
human body cannot synthesis them. Knowing lipid biochemistry and its metabolic 
disorder (dyslipidemia) is necessary in understanding the biomedical areas of non-
communicable disease like hypertension, diabetes, cancer, cardiovascular disease, 
obesity, nutritional value of unsaturated fatty acids and others [8].
According to the world health organization 2015 report non-communicable 
disease (NCDs) are responsible for up to 70% of deaths and these are hypertension, 
cardiovascular diseases, cancer, diabetes and chronic respiratory diseases. Majority 
of NCDs cases and deaths are observed in low- and middle-income countries. The 
report shows that tobacco, insufficient physical activity, harmful use of alcohol, 
unhealthy diet, raised blood pressure, overweight and obesity, raised cholesterol, 
cancer-associated infections and others are the major risk factors for NCDs [9, 10].
Number of studies showed that dyslipidemia used as a biomarker and risk factor 
for different NCDs and it is highly associated with one or more hormone disfunc-
tion. For example, deficiency or defect in insulin action among diabetes induce 
dyslipidemia and it is one of the major risk factors for cardiovascular disease. 
Dyslipidemia is the common finding among different types of diabetes. Across 
suctional study done by Hrishow et al. found that 73% male and 71% female of 
diabetic patients were dyslipidemic [11]. Another similar study done by Bekele S. 
et al. in Ethiopia revealed that 65.6% of diabetic patients were dyslipidemic. Plasma 
level of LDL, total cholesterol and triacyclglycerols were higher while HDL was 
lower among diabetic patients [12]. Similarly, number of recent studies showed that 
dyslipidemia has significant association with cancer and progress of the disease. 
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Lipids are major constituents of cell and disorder in lipid metabolism can affect the 
normal integration of cell which may leads to cancerous. On the other side treat-
ment for cancer patients specially chemotherapy induce dyslipidemia. In addition, 
oxidative modification of lipoprotein induces different inflammatory pathways and 
this enhance cell proliferation and migration and inhibit normal cell apoptosis [13]. 
Review done by Cedó L. et al. indicated that higher total serum cholesterol level 
is linked with higher risk of colorectum, colon, prostate and testicular cancer and 
lower risk of stomach, liver and hematopoietic and lymphoid tissues cancer. There 
was positive association between serum triglycerides and esophageal, colorectal, 
lung, renal, thyroid cancer [14]. Effective management of cholesterol may help to 
control the risk of cancer cases. Study by Macleod LC et al. stated that elevated LDL 
and impaired fasting glucose are highly associated with prostate cancer and man-
agement on them help to get better treatment outcome at the end [15].
Number of studies explained that dyslipidemia is a common risk factor for 
different types of cardiovascular disease. A 6 year follow up prospective cohort 
study done by Hedayatnia M et al. explained that serum LDL-C, TC, and TG levels 
were positively associated with the risk of total CVD events and the primary target 
of lipid-lowering therapy with statin is to reduce risk of CVD [16, 17]. Events of 
dyslipidemia occurred among patients with different infectious disease like HIV 
and TB increase risk of atherosclerosis and finally leads CVD. The infectious disease 
itself and the drugs given for that are responsible to induce dyslipidemia [18, 19].
1.2 Effect of dyslipidemia on vital organs
Survival of living organism like humans relies on wellbeing of vital internal 
organs; brain, liver, heart, lung and others. An organ which exists in most multicel-
lular organisms is a collection of tissues joined in a structural unit to serve a com-
mon function. Normal and functional liver is responsible for healthy metabolism of 
lipids. Study done by Unger LW et al showed that liver health is a major determinant 
of dyslipidemia patterns and prevalence. All etiology that induces advanced chronic 
liver disease significantly decrease total cholesterol levels when compared to normal 
[20]. Dyslipidemia can cause fatty liver disease and the reverse also possible. A 
multicenter retrospective cross-sectional study done for 5 years by Méndez-Sánchez 
N et al showed that dyslipidemia was the very common risk factor which is directly 
associated with advanced liver disease and cirrhosis [21].
Brain is one of very important vital organ for normal function of all other body 
organ and organ system. Studies indicated that dyslipidemia can affect the integrity 
and function of brain and significantly associated with number brain disorder like 
Alzheimer’s Disease. A one year follow up study done on 36 subjects with Alzheimer’s 
Disease by Bowman GL. et al confirmed that dyslipidemia was highly prevalent and 
more than 75% of them showed blood brain barrier (BBB) impairment. According 
to this study triglyceride and HDL cholesterol which have a role in maintaining 
BBB integrity were significantly higher among subjects with BBB impairment [22]. 
A Meta-Meta-Analysis done by Vazquez OS et al conclude that LDL-C cholesterol 
levels significantly increase the risk for development of Alzheimer’s disease. 
Hypercholesterolemia affect the normal function of vascular system and have 
neurotoxic effect thereby induce dementia and cognitive loss in Alzheimer’s Disease 
patients. In addition, coronary heart disease and carotid artery atherosclerosis raised 
as a result of hypercholesterolemia and that can lead to cognitive disorder by causing 
cerebral embolism or hypoperfusion which are associated with Alzheimer’s Disease 
incidence and prevalence [23]. Studies also showed that there is significant associa-
tion between high total cholesterol and LDL-cholesterol with different types of 
stroke as a result people with hypercholesterolemia have advised to take potent lipid 
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lowering drugs mainly statin to reduce risk of stroke. But there is an evidence that 
low level of total cholesterol can induce hemorrhagic stroke. Cohort study for one 
year on Patients with Transient Ischemic Attack done by Sirimarco G. et al showed 
that atherogenic dyslipidemia was significantly associated with intracranial artery 
stenosis and higher risk of early recurrent stroke. In general disorder in lipid metabo-
lism have a complex relationship with cerebrovascular disease [24, 25].
Bones which are found in different shapes and sizes have many roles in wellbe-
ing life and its health has intimate association with normal metabolism of lipids. 
Evidence indicated that highly increased adipocyte can be independent risk factor 
for osteoporosis and disorder of bone metabolism [26, 27]. Oxidation products of 
lipids as a result of hyperlipidemia can be accumulated in the subendothelial spaces 
of vasculature and bone and these affect the normal developments of bone nega-
tively. Study done on mice by Pirih F et al explain as dyslipidemia is one risk factor 
for thyroid dysfunction and impairs regeneration and mechanical strength of bone 
[28]. Another study done on rabbit to study the effect of hyperlipidemia on quality 
and quantity of bone and wound healing condition showed that hyperlipidemia 
negatively affect bone implant stability and pre-implant stability [29].
1.3 Dyslipidemia induce endocrine dysfunction
Disorder in lipid metabolism is a multifactorial problem; genetic and environ-
mental risk factors are very important modulators. Number of studies explain that 
dyslipidemia has significant association with age, sex and educational status and 
others. Dyslipidemia affect the normal health in number of ways and the mecha-
nism is complex. Diabetes, cardiovascular disease, hypertension and other noncom-
municable disease have direct or indirect relation with dyslipidemia. And most 
of non-communicable disease have endocrine bases; as a result, deep analysis of 
endocrine disorder and dyslipidemia is very crucial. For example, in cancers of the 
breast, prostate, testes, cervices, pancreas, thyroid and others patients have abnor-
mal lipid profile and all the cases have hormonal problems. A cross sectional study 
done by Altahir WHM et al showed that triacylglycerol was significantly higher 
while cholesterol was lower among hyperthyroidism patients [30]. Also, other 
cross-sectional study done by Khan MAH et al indicate as there is strong association 
between dyslipidemia and hypothyroidism [31].
There is clear evidence as chronic elevation of triacylglycerol in the blood cause 
islet alpha- and beta-cells dysfunction. In the general obese population; fasting level 
of insulin and glucagon have positive correlation with lipid parameters. Level of glu-
cagon is clear informative of glucose tolerance and the mechanism how elevated fatty 
acids affect islet-cells is through inactivation of G-protein coupled receptor called Free 
fatty acid receptor 1 (FFAR1) [32]. Cholesterol can modulate different metabolic path-
ways like signal transduction and gene expression in numbers of ways. Many studies 
showed that cholesterol level in the blood affect the secretion and function of insulin 
from beta-cell of pancreas. Animal model study done by Hao M et al found that 
elevated level of cholesterol can significantly reduce insulin secretion and the condi-
tion can be restored with management of blood cholesterol. The suggested mechanism 
for this is through manipulation of neuronal nitric oxide synthase dimerization [33].
Steroid hormones like sex hormones are synthesized from cholesterol, so the 
normal concentration of cholesterol is responsible for normal sexual develop-
ment of an individual. Production, secretion and degradation of factors that are 
involved in function of sex hormones like Sex hormone-binding globulin (SHBG) 
are regulated with lipid panels of individual. Study done by Park G et al indicated 
that dyslipidemia negatively affect the level SHBG and these can disturb the normal 
developments children at pubertal stage [34].
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1.4 Endocrine disorder risk for dyslipidemia
An endocrine system secretes specific chemicals, called hormones into the blood 
and travel through the blood to target cells or tissues that they induce a particular 
response or action. Hormones involved in regulation of biological activities like 
growth, reproduction, metabolism of biomolecules (protein, lipids, carbohydrate, 
nucleic acids and others). Endocrine disorders are among the most common 
medical problems faced by individual in both sexes. Defect in synthesis, storage, 
secretion and action of hormones can seriously affects normal biological activities 
of individuals in number of ways. One of the most important system affected as a 
result of endocrine disorder is lipid metabolism and these in turn risk for develop-
ments of different non-communicable diseases. Diabetes mellitus is one common 
endocrinological disorder and it leads to dyslipidemia. Cross-sectional study done 
by Xi Y et al showed that all types of diabetes and postmenopausal hormonal 
changes are positively correlated with dyslipidemia [35]. Hormones regulate 
expression of lipoprotein receptors, apoproteins, enzymes and control circulating 
triacylglycerol and glucose. Typical hormones involved in modulating lipid metabo-
lism are leptin, insulin, adiponectin, glucagon, catecholamines, cortisol and growth 
hormone and any disorder on these hormones’ synthesis, storage, secretion and 
action leads to dyslipidemia. Body lipid synthesis and degradation are under control 
of the above hormonal activity [36, 37]. Number of studies confirmed that dyslip-
idemia is the most common disorder among diabetes especially type 2 diabetes. As a 
result, people with diabetes should monitor their blood lipid levels regularly and get 
nutrition education periodically to prevent and control dyslipidemia [38].
Higher level of growth hormone and factors like insulin like growth factor-
1(IGF-1) leads to a medical problem called acromegaly. And these conditions alter 
the metabolism of biomolecules and activity of other hormones like insulin thereby 
risk for cardiovascular disease mainly by inducing dyslipidemia. Study done by 
Keskin H et al explained that LDL-C, triglyceride, IGF-1 level was significantly 
higher among acromegaly patients than control groups while HDL-C level was 
lower. In addition, growth hormone has positive correlation with LDL-C and 
triglyceride and negative correlation with HDL-C level [39].
One important steroid hormone called cortisol is responsible to regulates a 
wide range of vital biological processes including metabolism of biomolecules and 
immune response throughout the body. Cortisol is made in the cortex of the adrenal 
glands and released into the blood. Most of body cells have receptor for cortisol so 
that it produces different effect. Cortisol secretion regulated by close interaction 
of hypothalamus, pituitary gland and adrenal gland. One of the metabolic process 
regulated by cortisol is lipid metabolism. Study done by Djurhuus C. B. showed that 
cortisol is a potent stimulus of lipolysis in both femoral and abdominal adipose tissue 
[40]. Hypersecretion of cortisol which resulted from altered function of hypothala-
mus, pituitary gland and adrenal gland can leads to dyslipidemia. The mechanism 
by which cortisol disturb lipid metabolism is vary; initiate lipolysis, free fatty acid 
production and turnover, VLDL synthesis and fatty accumulation in liver and 
adipose tissue. Modulation of insulin sensitivity and adenosine monophosphate kinas 
(AMPK) activities are the key by which glucocorticoid-induced dyslipidemia will 
develop. In addition, defects of the glucocorticoid receptor affecting cortisol sensitiv-
ity is involved in lipid metabolism disorder and risk for cardiovascular disease [41].
Similarly, sex hormones are responsible in regulating metabolism lipids 
and any disorder regarding these sex hormones leads to dyslipidemia. In study 
done by Yeasmin N et al showed that serum total cholesterol and triacylglycerol 
level were significant higher in postmenopausal women than premenopausal 
women and they have negative correlation with serum estrogen as a result of this 
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postmenopausal women are more prone to have CVD and associated complications 
and  recommended to monitor their lipid profile regularly [42, 43].
1.5 Assessment of lipid profile as marker for endocrine disease
Lipids are a group of fats and fat-like substances that are important constituents 
of cells and sources of energy. Assessments lipid panel is simply qualitative and 
quantitative determination of the specific lipid parameters in the blood. Lipid 
profile test commonly performed to evaluate cardiovascular diseases including 
coronary heart disease (CHD), myocardial infarction (MI), coronary insufficiency, 
angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral 
artery disease (PAD) and heart failure. Directly or indirectly all the above cases 
related with endocrine disorder. In addition, evaluation of TG/HDL-C and TC/
HDL-C ratios are useful markers of metabolic syndrome with high predictive value 
in general population. Studies showed that LDL-C, total cholesterol, triglyceride 
and apolipoproteinB (apoB) can serves as biomarker Cushing syndrome [44]. 
Similarly, one or more lipid profile abnormality is common prior to type 2 diabetes 
[45]. In general, in most of endocrine disease dyslipidemia is common and physician 
who suspect his patients have hormonal problem should order lipid profile test [46].
1.6 Conclusion
Dyslipidemia is an abnormal amount of lipids commonly triglycerides, cho-
lesterol LDL-C, HDL.C and other in the blood and it is highly prevalent among 
patients with noncommunicable disease. Each and every lipid profile parameter 
abnormality has direct or indirect relation with endocrine disorder. Even though 
it needs more extended research disorder in lipid metabolism induce hormonal 
dysfunction and the reverse also possible.
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